GSK
GSK is a science-led global healthcare company headquartered in Brentford, Hounslow, United Kingdom. It focuses on the research and development of innovative medicines, vaccines, and consumer healthcare products, serving millions of people worldwide. The company operates in three primary business areas: pharmaceuticals, vaccines, and consumer healthcare, and ranks among the largest firms in the pharmaceutical industry by total sales. GSK's product portfolio includes treatments across several therapeutic classes, such as respiratory, cancer, and antiviral medicines, as well as vaccines. The company emphasizes the importance of research, investing heavily in the development of new products to enhance accessibility and improve health outcomes. With a global presence that includes offices in over 115 countries and major research centers in the UK, USA, Spain, Belgium, and China, GSK maintains a significant manufacturing network with 87 sites worldwide. Through joint ventures, GSK aims to expand its scale in specific markets, including HIV.
Sitryx Therapeutics is a biopharmaceutical company established in 2018 and based in Oxford, United Kingdom. It focuses on developing disease-modifying therapeutics in the fields of immuno-oncology and immuno-inflammation by regulating cell metabolism. The company aims to correct and alter immune cell functions to inhibit tumor growth. Co-founded by renowned scientists from the United States and Europe, Sitryx has garnered significant funding, including a $30 million Series A round from various specialist investors. The company is actively engaged in multiple stages of drug discovery, working on a diverse pipeline of projects aimed at addressing unmet medical needs in immunometabolism.
Calporta Therapeutics
Series A in 2015
Calporta is developing selective small molecule agonists of TRPML1 (transient receptor potential cation channel, mucolipin subfamily, member 1) for the treatment of Niemann-Pick C Disease (NPC) and other lysosomal storage diseases. Mutations that cause NPC lead to impaired intracellular lipid trafficking and lead to lysosomal accumulation of cholesterol and biolipds. TRPML1 is an ion channel in the lysosome and a key regulator of lysosomal trafficking processes. Impaired TRPML1 function has been implicated in multiple pathological conditions, including NPC. Agonists of TRPML1 restore calcium efflux and normalize lysosomal trafficking and function. In addition to NPC and other lysosomal storage diseases, agonists of TRPML1 may have broad potential in other diseases such as muscular dystrophy and various taopathies such as Alzheimer's disease. Calporta's approach is based on research from the lab of Haoxing Xu, Ph.D., at the University of Michigan.
Cadherx Therapeutics
Series A in 2015
Develops therapeutic antibodies targeting soluble E-cadherin.
Thrasos is a bio-therapeutics company dedicated to discovering and developing targeted therapies for severe organ failure, with a primary emphasis on kidney diseases. The company's lead program, THR-184, aims to prevent and treat acute kidney injury (AKI). Additionally, Thrasos is advancing a preclinical development program that addresses chronic kidney disease (CKD). The company also focuses on developing innovative treatments for rare kidney-related conditions, such as myeloma cast nephropathy, which occurs when protein aggregates obstruct renal tubules, leading to the risk of permanent kidney damage. Through its efforts, Thrasos seeks to provide timely and effective treatment options for patients suffering from these serious kidney issues.
SpringLeaf Therapeutics (formerly known as Entra Pharmaceuticals, Inc.) is creating innovative therapeutic modalities to address serious disease and elevate the quality of care for patients. SpringLeaf's technology is based on convergent science and is designed to enable and differentiate therapeutics. SpringLeaf was founded based on breakthrough science at MIT and is backed by leading investors including Flybridge Capital Partners and North Bridge Venture Partners.
Anacor Pharmaceuticals is a biopharmaceutical company that engages in developing small-molecule therapeutics from its boron chemistry platform. It focuses on developing topical applications of its compounds to treat fungal, bacterial, and inflammatory diseases.
The company’s primary product candidate, AN2690, is a novel topical antifungal for the treatment of toenail onychomycosis, a fungal infection of the nail and nail bed. It is also developing AN2728, an anti-inflammatory product candidate for the treatment of psoriasis; AN0128, a product candidate that has antibiotic and anti-inflammatory properties; and AN2718, which is in preclinical development for the topical treatment of vaginal candidiasis and tineapedis.
diaDexus is a biotechnology company specializing in the development and commercialization of diagnostic products for cardiovascular disease. Its primary offering, the PLAC Test, measures Lp-PLA2, an enzyme linked to plaque formation in arteries, providing valuable insights into the risk of coronary heart disease and ischemic stroke. This test is notable for being the only blood test cleared by the FDA for assessing these risks. In addition to cardiovascular diagnostics, diaDexus also develops test kits for a range of other health conditions, including liver disease, cancer markers, renal disease, diabetes, and electrolytes. The company primarily operates in the United States, which constitutes the majority of its revenue, while also maintaining a presence in Europe and other regions worldwide.
Anacor Pharmaceuticals is a biopharmaceutical company that engages in developing small-molecule therapeutics from its boron chemistry platform. It focuses on developing topical applications of its compounds to treat fungal, bacterial, and inflammatory diseases.
The company’s primary product candidate, AN2690, is a novel topical antifungal for the treatment of toenail onychomycosis, a fungal infection of the nail and nail bed. It is also developing AN2728, an anti-inflammatory product candidate for the treatment of psoriasis; AN0128, a product candidate that has antibiotic and anti-inflammatory properties; and AN2718, which is in preclinical development for the topical treatment of vaginal candidiasis and tineapedis.
Concert Pharmaceuticals is a clinical-stage biopharmaceutical company based in Lexington, Massachusetts, founded in 2006. The company focuses on discovering and developing novel small-molecule drugs primarily for autoimmune and central nervous system disorders. Its key product candidates include CTP-543, currently in Phase III trials for alopecia areata; CTP-692, in Phase II trials for schizophrenia; and AVP-786, which is undergoing Phase III trials for various neurologic and psychiatric conditions, including agitation related to Alzheimer’s disease. Concert employs a unique precision deuterium chemistry platform to modify existing drug molecules, aiming to enhance efficacy and safety while reducing research and development risks. The company also maintains strategic collaborations with several pharmaceutical partners to further its research and development efforts.
CalciMedica, Inc. is a biotechnology company based in La Jolla, California, focused on the discovery and development of small molecule drugs aimed at treating autoimmune and inflammatory diseases. Founded in December 2006 by a team of scientists with backgrounds in calcium signaling, the company specializes in the targeted inhibition of calcium release-activated calcium channels, a key mechanism in immune response regulation. The founding team includes individuals who previously collaborated at TorreyPines Therapeutics and the CBR Institute, where they made significant contributions to understanding calcium signaling pathways. Through its innovative research, CalciMedica aims to develop effective therapies for patients suffering from various autoimmune conditions.
diaDexus is a biotechnology company specializing in the development and commercialization of diagnostic products for cardiovascular disease. Its primary offering, the PLAC Test, measures Lp-PLA2, an enzyme linked to plaque formation in arteries, providing valuable insights into the risk of coronary heart disease and ischemic stroke. This test is notable for being the only blood test cleared by the FDA for assessing these risks. In addition to cardiovascular diagnostics, diaDexus also develops test kits for a range of other health conditions, including liver disease, cancer markers, renal disease, diabetes, and electrolytes. The company primarily operates in the United States, which constitutes the majority of its revenue, while also maintaining a presence in Europe and other regions worldwide.
Resistentia Pharmaceuticals
Series C in 2006
Resistentia Pharmaceuticals, a biopharmaceutical company, develops immunotherapeutic products for allergic asthma and inflammatory disorders. It provides Immunoglobulin E for allergic reactions, including asthma, rhinitis, and dermatitis; and C5a for the treatment of inflammatory conditions, such as rheumatoid arthritis, asthma, and multiple sclerosis. Resistentia Pharmaceuticals AB was founded in 1998 and is based in Uppsala, Sweden.
Trinity Biosystems, Inc. engages in the development and formulation of oral therapeutic proteins. It involves in developing vaccines in the areas of respiratory, digestive, and sexually transmitted diseases, as well as transporting proteins, peptides, and other macromolecules. The company was founded in 2002 and is based in Menlo Park, California.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.